Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Key Inclusion Criteria:

• Men and women ≥ age 40 years and ≤ age 85 years
• Patients with heterozygous familial hypercholesterolemia (heFH) or with non-familialhypercholesterolemia (non-FH) patients at high or very high cardiovascular risk
• Patients with history of coronary heart disease (CHD) not having adequate control oftheir hypercholesterolemia with LDL-C ≥70 mg/dL, or all other patients with LDL-C ≥100mg/dL and be on maximally-tolerated dose of statin (unless they are statin-intolerant)
• Patients must have successfully completed the Motor Screening Task
• Patients must be willing and able to comply with clinic visits and study relatedprocedures
• Patients must provide signed informed consent

Key Exclusion Criteria:

• Patients with known Alzheimer's disease or other dementia, schizophrenia, bipolardisorder, severe depression, cognitive impairment, or patients with a sleep disorderrequiring daily pharmacological treatment
• Recent (within 3 months prior to the screening visit) myocardial infarction, unstableangina leading to hospitalization, coronary artery bypass graft surgery, percutaneouscoronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting,stroke, transient ischemic attack, carotid revascularization, endovascular procedureor surgical intervention for peripheral vascular disease
• Certain laboratory findings obtained during the screening visit as defined in theprotocol
• Any condition or situation, including other significant mental or neurologicaldisorders that, in the investigator's opinion, may confound the study results, or mayinterfere significantly with the patient's participation in the study
• Pregnant or breastfeeding women
• A positive human immunodeficiency virus (HIV) test NOTE: Other protocol defined Inclusion/Exclusion Criteria apply